1,538,247 Shares in ProQR Therapeutics (NASDAQ:PRQR) Bought by Platinum Investment Management Ltd.

Platinum Investment Management Ltd. acquired a new position in shares of ProQR Therapeutics (NASDAQ:PRQR) in the fourth quarter, Holdings Channel reports. The firm acquired 1,538,247 shares of the biopharmaceutical company’s stock, valued at approximately $4,076,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PRQR. OneDigital Investment Advisors LLC lifted its holdings in shares of ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 15,550 shares during the period. BNP Paribas Financial Markets raised its position in ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 7,300 shares in the last quarter. Ballentine Partners LLC purchased a new stake in shares of ProQR Therapeutics in the fourth quarter valued at approximately $61,000. M&T Bank Corp purchased a new stake in shares of ProQR Therapeutics in the fourth quarter valued at approximately $330,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of ProQR Therapeutics in the fourth quarter valued at approximately $260,000. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Trading Down 3.5 %

PRQR stock opened at $1.64 on Wednesday. The company has a market capitalization of $133.96 million, a PE ratio of -5.13 and a beta of 0.24. ProQR Therapeutics has a 12-month low of $1.61 and a 12-month high of $4.62. The business’s fifty day moving average price is $2.21 and its 200 day moving average price is $2.62.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on PRQR shares. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research note on Friday, March 14th. Oppenheimer assumed coverage on ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 price target on the stock. StockNews.com lowered ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Finally, Citigroup raised ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.50.

ProQR Therapeutics Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).